Sanofi records €1B+ write-off, ends work on two immunology assets

Negative

AI Analysis

Summary

Sanofi recorded over €1.03 billion in impairment charges in Q2 primarily due to terminating an eczema drug and winding down two other immunology assets following a pipeline review.

Outcome Details

Pipeline review leading to termination of eczema drug and wind-down of two immunology drugs

Importance:5/10

Sentiment:

-0.80

impairment chargespipeline terminationimmunologyeczemaQ2 earnings

Related Companies

$SNY

Read the original article

Published by Endpoints News on July 30, 2026 9:35 AM

Read Original